Mirae Asset Global ETFs Holdings
AVDL

Mirae Asset Global ETFs Holdings’s Avadel Pharmaceuticals AVDL Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,462
Closed -$894K – 3126
2025
Q4 		$894K Sell
41,462
-44
-0.1% -$854 ﹤0.01% 1583
2025
Q3 		$634K Sell
41,506
-7,444
-15% -$96.9K ﹤0.01% 1753
2025
Q2 		$433K Sell
48,950
-5,935
-11% -$52.1K ﹤0.01% 1893
2025
Q1 		$430K Buy
54,885
+2,291
+4% +$19.2K ﹤0.01% 1950
2024
Q4 		$553K Buy
52,594
+1,882
+4% +$22.9K ﹤0.01% 1862
2024
Q3 		$665K Buy
+50,712
New +$772K ﹤0.01% 1768

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's AVDL Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 41,462 shares — an estimated $894K sold.

Mirae Asset Global ETFs Holdings first reported a position in AVDL in Q3 2024 and held it in 6 quarters. The position peaked at $894K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Mirae Asset Global ETFs Holdings reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 41,462 Avadel Pharmaceuticals shares in Q1 2026, an estimated $894K.
  • Mirae Asset Global ETFs Holdings first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Mirae Asset Global ETFs Holdings's Avadel Pharmaceuticals position peaked at $894K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.